Otsuka Pharmaceutical Acquires Mindset Pharma

Otsuka Pharmaceutical Acquires Transcend Therapeutics

March 27, 2026

Biotechnology

Otsuka Pharmaceutical Co., Ltd. entered into an agreement to acquire clinical-stage biotech company Transcend Therapeutics, which is developing rapid-acting treatments for neuropsychiatric disorders, including its lead program TSND-201 (methylone) for PTSD. Otsuka would pay $700 million upfront at closing and up to $525 million in contingent milestone payments, with completion expected in Q2 2026; the acquisition has since been completed.

Tanabe Consulting Group Acquires Majority Stake in PEACEMIND

May 26, 2025

Healthcare Services

Tanabe Consulting Group (TSE Prime) agreed to acquire a majority stake in PEACEMIND Inc., making it a subsidiary, and to enter a capital and business alliance. The deal is intended to expand Tanabe’s “corporate well-being” and HR consulting capabilities by combining management consulting with PEACEMIND’s EAP and Working Better Cloud platform.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Beatrice Society Acquires MindSetting

November 15, 2021

Healthcare Services

Toronto-based Beatrice Society has acquired Canadian psychedelic-assisted psychotherapy provider MindSetting to accelerate adoption of the MindSetting TRIP Protocol and expand clinician training and psychedelic-enhanced therapy offerings. The acquisition brings MindSetting’s protocol certification program and clinic experience into Beatrice’s education and consumer/therapy-focused platform to broaden clinical access to ketamine-assisted and other psychedelic therapies across Canada.

Community Psychiatry Acquires MindPath Care Centers

May 11, 2021

Healthcare Services

Community Psychiatry Management, LLC acquired MindPath Care Centers to create a nationally scaled outpatient behavioral health platform, more than doubling locations to 70+ and combining over 350 clinicians. The deal expands access to in-person and telemedicine mental health services, including psychiatry, psychotherapy, TMS and addiction recovery, and positions the combined organization for further growth following Community Psychiatry's recent strategic capital investment.

NewLeaf Brands to Acquire Mindleap Health Inc.

May 20, 2020

Healthcare Services

NewLeaf Brands Inc. signed a non-binding letter of intent to acquire 100% of Mindleap Health Inc. via a share exchange, with consideration of CAD $3.5 million in NewLeaf common shares plus additional cash investments. Mindleap is a digital mental-health and telehealth platform focused on mood, emotion and habit tracking and psychedelic aftercare, and the deal is intended to accelerate Mindleap’s time-to-market and expand NewLeaf’s digital health capabilities.